论文部分内容阅读
乳腺癌是全世界女性最常见的恶性肿瘤之一。Toll样受体(Toll-like receptor,TLR),存在于淋巴细胞、自然杀伤细胞(natural killer cell,NK)、树突状细胞(dendritic cell,DC)和巨噬细胞,是调节天然免疫与适应性免疫、炎症与乳腺癌之间的桥梁。TLR的多态性关联乳腺癌的易感性,影响与乳腺癌细胞增殖、入侵和转移等密切相关的信号蛋白和因子,包括p53、NF-κB、MMP和ROS,调节下游信号分子的表达,激活炎症通路和创造良好的肿瘤微环境,进而影响乳腺癌的发生发展。TLR可能成为乳腺癌治疗的潜在药物治疗靶点。本文结合最新研究,对TLR及其在乳腺癌中的作用和治疗现状予以阐述。
Breast cancer is one of the most common malignancies in the world for women. Toll-like receptors (TLRs), which exist in lymphocytes, natural killer cells (NKs), dendritic cells (DCs) and macrophages, regulate innate immunity and adaptation Immunity, a bridge between inflammation and breast cancer. TLR polymorphisms are associated with the susceptibility of breast cancer and affect the signal proteins and factors closely related to breast cancer cell proliferation, invasion and metastasis, including p53, NF-κB, MMP and ROS, regulate the expression of downstream signaling molecules, activate Inflammatory pathways and create a good tumor microenvironment, thereby affecting the occurrence and development of breast cancer. TLR may be a potential therapeutic target for the treatment of breast cancer. This article combines the latest research on the TLR and its role in breast cancer and treatment status are described.